Lancet and ChemRar partner on development and production of novel drugs in Russia

16 April 2015

ChemRar High Tech Center (ChemRar), a Russian pharma investment and R&D group, and local distributor Lancet have agreed to collaborate for research, development and commercialization of new medicines in Russia with the intention to stimulate the innovative development of the Russian pharmaceutical industry.

Through the partnership ChemRar and Lancet plan to develop and manufacture new drugs in major therapeutic areas which are a high priority for the Russian Federation health care system according to the significant government strategy PHARMA-2020. The parties have agreed to co-invest in the further development of manufacturing capacities in order to localize the pharmaceutical production in the Russian Federation. The companies are supposed to carry out joint activity with use of complementary competences in development, production, distribution and marketing of innovative medicines in Russia and EEU (the Eurasian Economic Union).

Hope to successfully transform scientific achievements into quality products

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK